Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,291.80GBp
30 Oct 2020
Change (% chg)

-12.40 (-0.95%)
Prev Close
1,304.20
Open
1,295.20
Day's High
1,305.20
Day's Low
1,284.00
Volume
8,312,632
Avg. Vol
6,218,125
52-wk High
1,857.00
52-wk Low
1,284.00

Latest Key Developments (Source: Significant Developments)

GSK Nucala Filings Accepted By EMA For Three Additional Eosinophil-Driven Diseases
Thursday, 29 Oct 2020 

Oct 29 (Reuters) - GlaxoSmithKline PLC ::GSK NUCALA (MEPOLIZUMAB) FILINGS ACCEPTED BY EUROPEAN MEDICINES AGENCY FOR THREE ADDITIONAL EOSINOPHIL-DRIVEN DISEASES.  Full Article

GSK's Zejula Get EC Approval As First-Line Monotherapy Maintenance Treatment In Advanced Ovarian Cancer
Thursday, 29 Oct 2020 

Oct 29 (Reuters) - GlaxoSmithKline PLC ::GSK - EUROPEAN COMMISSION APPROVES ZEJULA (NIRAPARIB) AS FIRST-LINE MONOTHERAPY MAINTENANCE TREATMENT IN ADVANCED OVARIAN CANCER .  Full Article

GSK Sees FY2020 Adj EPS At Lower End Of -1% To -4% Range At CER
Wednesday, 28 Oct 2020 

Oct 28 (Reuters) - GlaxoSmithKline PLC ::Q3 REVENUE 8.646 BILLION STG.Q3 EPS FELL 9 PERCENT TO 25 PENCE.Q3 ADJUSTED EPS ROSE 1 PERCENT TO 35.6 PENCE.GSK - ON TRACK TO DELIVER FULL YEAR 2020 ADJUSTED EPS AT LOWER END OF -1% TO -4% RANGE AT CER.GSK - 19P DIVIDEND DECLARED FOR QUARTER.GSK - 19P DIVIDEND DECLARED FOR QUARTER.GSK - QTRLY SHINGRIX SALES £374 MILLION, -30% AER, -25% CER..GSK - PHASE I/II STUDY OF SANOFI-GSK ADJUVANTED RECOMBINANT PROTEIN-BASED VACCINE CANDIDATE INITIATED. PHASE III TRIAL EXPECTED TO START DECEMBER 2020.GSK - QTRLY SALES FROM PHARMACEUTICALS £4.2 BILLION, -7% AER, -3% CER.GSK - QTRLY SALES FROM VACCINES £2.0 BILLION, -12% AER, -9% CER.GSK - RESEARCH AND DEVELOPMENT COSTS DOWN IN QUARTER; EXPECT 2020 FULL YEAR RESEARCH AND DEVELOPMENT COSTS TO RISE.GSK - COVID-19 PANDEMIC HAS IMPACTED GROUP PERFORMANCE, PARTICULARLY IN VACCINES BUSINESS, DURING FIRST NINE MONTHS OF 2020.GSK - QTRLY SALES FROM CONSUMER HEALTHCARE £2.4 BILLION, -4% AER, +2% CER.GSK-PHASEIII STUDY UNDERWAY FOR VIR-GSK ANTIBODY (VIR-7831)FOR HIGH-RISK OUTPATIENTS WITH COVID19 INITIAL RESULTS POTENTIALLY AVAILABLE BY END OF 2020.GSK - COVID-19 PANDEMIC HAS IMPACTED GROUP PERFORMANCE, PARTICULARLY IN VACCINES BUSINESS, DURING FIRST NINE MONTHS OF 2020.GSK - CONTINUE TO MAKE GOOD PROGRESS ON OUR PREPARATIONS TO SEPARATE GROUP AND CREATE TWO NEW COMPANIES - IN BIOPHARMA AND CONSUMER HEALTH.GSK - IMPROVING VACCINATION RATES THIS QUARTER.  Full Article

BRIEF-Sanofi, GSK Sign Agreements With Canada For Up To 72 Million Doses Of Adjuvanted COVID-19 Vaccine
Tuesday, 22 Sep 2020 

Corrects sourcing to Sanofi in the text.:SANOFI AND GSK SIGN AGREEMENTS WITH THE GOVERNMENT OF CANADA TO SUPPLY UP TO 72 MILLION DOSES OF ADJUVANTED COVID-19 VACCINE.SIGNED AGREEMENTS RELATE TO VACCINE CANDIDATE USING SANOFI'S RECOMBINANT PROTEIN-BASED TECHNOLOGY COMBINED WITH GSK'S PANDEMIC ADJUVANT.  Full Article

GlaxoSmithKline Gets CHMP Positive Opinion Recommending Nod Of Zejula's First-Line Monotherapy Maintenance Treatment
Friday, 18 Sep 2020 

Sept 18 (Reuters) - GlaxoSmithKline PLC ::GSK - GETS CHMP POSITIVE OPINION RECOMMENDING APPROVAL OF ZEJULA S FIRST-LINE MONOTHERAPY MAINTENANCE TREATMENT.GSK - TREATMENT FOR WOMEN WITH PLATINUM-RESPONSIVE ADVANCED OVARIAN CANCER.  Full Article

Kymera Therapeutics Enters First Amendment To Collaboration Agreement With Glaxosmithkline Intellectual Property Development
Wednesday, 2 Sep 2020 

Sept 1 (Reuters) - GlaxoSmithKline PLC ::KYMERA THERAPEUTICS - ON AUG 27, ENTERED FIRST AMENDMENT TO COLLABORATION AGREEMENT WITH GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED.KYMERA THERAPEUTICS INC - GSK AMENDMENT PROVIDES EACH PARTY A RIGHT TO USE INSIGHTS GAINED THROUGH E3 LIGASE RESEARCH PLAN FOR ITS OWN PROGRAMS.KYMERA THERAPEUTICS - AMENDMENT PROVIDES FOR MANAGEMENT OF JOINTLY OWNED INTELLECTUAL PROPERTY RESULTING FROM CONDUCT OF E3 LIGASE RESEARCH PLAN.  Full Article

GSK says Sanofi, Co In Advanced Discussions With EU To Supply Up To 300 Mln Doses Of Covid-19 Vaccine
Saturday, 1 Aug 2020 

July 31 (Reuters) - Gsk ::SANOFI AND GSK IN ADVANCED DISCUSSIONS WITH EUROPEAN UNION TO SUPPLY UP TO 300 MILLION DOSES OF COVID-19 VACCINE.DISCUSSIONS RELATE TO VACCINE CANDIDATE USING SANOFI'S RECOMBINANT PROTEIN-BASED TECHNOLOGY COMBINED WITH GSK'S PANDEMIC ADJUVANT SYSTEM.DOSES WOULD BE MANUFACTURED IN EUROPEAN COUNTRIES INCLUDING FRANCE, BELGIUM, GERMANY AND ITALY.SANOFI EXPECTS A PHASE 1/ 2 STUDY TO START IN SEPTEMBER, FOLLOWED BY A PHASE 3 STUDY BY END OF 2020.IF DATA ARE POSITIVE, REGULATORY APPROVAL COULD BE ACHIEVED BY FIRST HALF OF 2021.SANOFI AND GSK ARE SCALING UP MANUFACTURING OF ANTIGEN AND ADJUVANT TO PRODUCE UP TO ONE BILLION DOSES PER YEAR OVERALL.  Full Article

GSK Says Expects To Supply More Than 50 Mln Doses Of Influenza Vaccines For U.S. Market In 2020-21 Season
Wednesday, 29 Jul 2020 

July 28 (Reuters) - GlaxoSmithKline PLC ::GSK - BEGINS SHIPPING RECORD NUMBER OF ITS INFLUENZA VACCINE DOSES FOR 2020-21 SEASON FOR U.S. MARKET.GSK - EXPECTS TO SUPPLY MORE THAN 50 MILLION DOSES OF INFLUENZA VACCINES FOR U.S. MARKET IN 2020-21 SEASON.  Full Article

GSK To Invest 130 Mln Stg In CureVac Under New Collaboration
Monday, 20 Jul 2020 

July 20 (Reuters) - GlaxoSmithKline Plc ::GSK AND CUREVAC ENTER COLLABORATION.GSK TO MAKE EQUITY INVESTMENT OF £130M (EUR 150M) IN CUREVAC, AND AN UPFRONT PAYMENT OF £104M (EUR 120M).COMPANIES TO COLLABORATE ON MRNA VACCINE AND MONOCLONAL ANTIBODY RESEARCH PROGRAMMES IN INFECTIOUS DISEASES.CUREVAC WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS OF UP TO £277M (EUR 320M).COMPANIES TO COLLABORATE ON MRNA VACCINE AND MONOCLONAL ANTIBODY RESEARCH PROGRAMMES IN INFECTIOUS DISEASES.CUREVAC WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS OF UP TO £277M (EUR 320M).GSK WILL FUND RESEARCH AND DEVELOPMENT ACTIVITIES AT CUREVAC RELATED TO DEVELOPMENT PROJECTS COVERED BY COLLABORATION.WILL MAKE AN EQUITY INVESTMENT IN CUREVAC OF £130M (EUR 150M), REPRESENTING CLOSE TO A 10% STAKE.  Full Article

GSK Says FDA Panel Votes In Favor Of Co's Blood Cancer Drug
Wednesday, 15 Jul 2020 

July 15 (Reuters) - GlaxoSmithKline Plc ::FDA PANEL VOTES IN FAVOR OF BELANTAMAB MAFODOTIN.RECOMMENDATION BASED ON REVIEW OF DREAMM CLINICAL TRIAL PROGRAMME, INCLUDING PIVOTAL DREAMM-2 STUDY.IF APPROVED, BELANTAMAB MAFODOTIN WILL BE A FIRST-IN-CLASS ANTI-BCMA THERAPY FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA.  Full Article

Photo

Activists urge 'Big Pharma' to be transparent on COVID-19 vaccine costs

GENEVA Activists called on pharmaceutical companies on Thursday to be transparent about the costs and terms of providing COVID-19 vaccines, saying they must be available and affordable for all.